Could a common bladder drug slow ALS? new trial underway

NCT ID NCT06249867

First seen Oct 01, 2025 · Last updated May 04, 2026 · Updated 23 times

Summary

This study tests a drug called darifenacin, typically used for overactive bladder, in 30 people with ALS. The goal is to see if it can help repair the connection between nerves and muscles, potentially slowing the disease and improving quality of life. Participants will take the drug or a placebo daily for 24 weeks, with regular checkups on safety and function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Montreal Neurological Institute

    RECRUITING

    Montreal, Quebec, H3A 2B4, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

  • Ottawa Hospital Research Institute

    RECRUITING

    Ottawa, Ontario, K1Y 4E9, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.